Background. The management of chronic myeloid leukemia (CML) has been revolutionized by tyrosine kinase inhibitors (TKIs), shifting the therapeutic goal from survival to achieving treatment-free remission (TFR). However, TFR is undermined by molecular relapse in 40–60% of patients, highlighting the imprecision of the current “gold standard” monitor, quantitative reverse-transcription PCR (qPCR), at the deep molecular response (DMR) level. Objective. The review systematically evaluates the comparative analytical and clinical performance of digital PCR (dPCR) versus qPCR for monitoring minimal residual disease (MRD) in CML. Methods. According to PRISMA-ScR guidelines, a systematic search of PubMed, Scopus, and Embase (from 2021 to present) was conducted, supplemented by a review of major clinical guidelines (ELN, NCCN, ESMO) from the last decade. Studies were selected for comparing dPCR and qPCR in the context of BCR-ABL1 quantification, DMR, and TFR. Results. The evidence demonstrates that dPCR is an analytically superior technology, offering absolute quantification that is more accurate, precise, and tolerant to amplification inhibitors than qPCR, especially at the very low levels of disease relevant to TFR decisions. Recent clinical data, most notably the experimental non-pharmacologic trial “DEep MOlecular respoNSe and TRAnscript Type Evaluation by digital PCR – Studio DEMONSTRATE”, establishes dPCR as a prognostically superior tool, capable of anticipating the achievement of a “true” and stable DMR by a median of 5 months compared to qPCR (p = 0.0017). This finding suggests dPCR can more accurately stratify patients, potentially averting TFR attempts in those with residual disease undetectable by qPCR. A significant “standardization lag” exists, wherein laboratory guidelines (ELN 2023) validate dPCR, but major clinical guidelines (NCCN 2024) have not yet integrated it into their primary monitoring algorithms. Conclusions. dPCR represents a significant clinical advance in CML monitoring. Its superior prognostic power to define stable DMR makes it an essential tool for enhancing the safety and success of TFR. The primary barrier to its widespread clinical adoption is no longer a lack of evidence, but the urgent, logistical need for methodological standardization and its formal integration into international clinical practice guidelines.